Remix.run Logo
▲ 233mhz 34 minutes ago

> For once, this isn’t hyperbole.

Am I missing something?

From other sources:

> Median overall survival: 13.2 months versus about 6.6 to 6.7 months with chemotherapy.

▲scarmig 31 minutes ago | parent | next [-]

Doubling life expectancy on a form of cancer infamous as a death sentence.

▲shevy-java 22 minutes ago | parent [-]

I don't see that as a breakthrough.

Merely counting months does not do much - you'd have to count the quality of these months too.

▲maxerickson 17 minutes ago | parent | next [-]

An effect that large is a medical breakthrough regardless of your opinion of the treatment impact.

▲simtel20 17 minutes ago | parent | prev [-]

Often pancreatic cancer is discovered only after it has spread. If this can treat it at that point it turns the disease from a death sentence to a lifeline until more research can come to fruition

▲tedggh 27 minutes ago | parent | prev | next [-]

Everything is relative. A few more months of life with less pain and more energy to spend it with family surely is a breakthrough for many patients and for the doctors treating them.

▲shevy-java 21 minutes ago | parent [-]

But where does it imply less pain? Plus, which pain exactly? Chemotherapy also leads to pain. Prolonging treatment can cause more pain then.

I don't see that as a breakthrough.

▲simtel20 13 minutes ago | parent | next [-]

You're awfully negative about what a lot of people here see as a breakthrough. Can you be more descriptive about why you don't agree this constitutes a substantial difference other than saying you disagree and dismissing others' opinion?

▲msdz 13 minutes ago | parent | prev | next [-]

I don’t think you have ever had to witness somebody undergoing chemotherapy. An alternative, if available is almost always better, and certainly less painful.

▲dgacmu 8 minutes ago | parent | prev [-]

It sucks less than existing chemo:

> Treatment-related adverse events that led to treatment discontinuation occurred in 1.2% of the patients in the daraxonrasib group and in 11.2% of those in the chemotherapy group.

That's a huge reduction in side effects bad enough to stop treatment.

https://www.nejm.org/doi/full/10.1056/NEJMoa2605555?

▲bonsai_spool 20 minutes ago | parent | prev [-]

That’s like a 100% increase over standard of care. Or a two-order-of-magnitude improvement.

▲csallen 15 minutes ago | parent [-]

It's a 2× increase. Huge, but not two orders of magnitude, which would be a 100× increase.

▲hyperhello 9 minutes ago | parent [-]

In base sqrt(2) it is two orders I guess.